References
- Duke O., Panayi G. S., Janossy G., Poulter L. W. An immunohistological analysis of lymphocyte subpopulations and their microenvironment in the synovial membranes of patients with rheumatoid arthritis using monoclonal antibodies. Clin Exp Immunol 1982; 49: 22–30
- Romangnani S. Biology of human Th1 and Th2 cells. J Clin Immunol 1995; 15: 121–9
- Dolhain, van der Heiden A., ter Hsar N. T., Breodved F. C., Miltenburg A. M. M. Shift towards T lymphocytes with a T helper 1 cytokine secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 1961–9
- Koops H. S., Davis L. S., Haverty T. P., Wacholtz M. C., Lipsky P. E. Reduction of Th1 cell activity in the peripheral circulation of patients with RA after treatment with a non‐depleting humanized monoclonal antibody to CD4. J Rheumatol 1998; 25: 2065–76
- Andre V., Sylvain L. The SLAM family of immune‐cell receptors. Curr Opin Immunol 2003; 15: 277–85
- Cocks B. G., Chang C. J., Carballido J. M., Yssel H., de Vries J. E., Aversa G. A novel receptor involved in T‐cell activation. Nature 1995; 376: 260–3
- Gerards A. H., de Lathouder S., de Groot E. R., Dijkmans B. A. C., Aarden L. A. Inhibition of cytokine production by methotrexate. Rheumatology 2003; 42: 1189–96
- Dolhain R. J. E. M., Tak P. P., Dijkmans B. A. C., de Kuiper P., Breedveld F. C., Miltenburg A. M. M. Methotrexate reduced inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. Br J Rheumatol 1998; 37: 502–8
- Morgan S. L., Oster R. A., Lee J. Y., Alarcon G. S., Baggott J. E. The effect of folinic acid supplements on purine metabolism in methotrexate‐treated rheumatoid arthritis. Arthritis Rheum 2004; 50: 3104–11
- Danning C. L., Boumpas D. T. Commonly used disease‐modifying antirheumatic drugs in the treatment of inflammatory arthritis: an update on mechanisms of action. Clin Exp Rheumatol 1998; 16: 595–604
- Mavaddat N., Mason D. W., Arkinson P. D., Evans E. J., Gilbert R. J. C., Stuart D. I., et al. Signaling lymphocytic activation molecule (CDw150) is homophilic but self‐associates with very low affinity. J Biol Chem 2000; 275: 28100–9
- Johnston A., Gudjonsson J. E., Sigmundsdottir H., Ludviksson B. R., Valdimarsson H. The anti‐inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 2005; 114: 154–63
- Isomaki P., Aversa G., Cocks B. G., Luukkainen R., Saario R., Toivanen P., et al. Increased expression of signaling lymphocytic activation molecule in patients with rheumatoid arthritis and its role in the regulation of cytokine production in rheumatoid synovium. J Immunol 1997; 159: 2986–93
- Svendsen K. B., Ellingsen T., Bech J. N., Pfeiffer‐Jensen M., Stengaard‐Pedersen K., Pedersen E. B. Urinary excretion of α‐GST and albumin in rheumatoid arthritis patients treated with methotrexate or other DMARDs alone or in combination with NSAIDs. Scand J Rheumatol 2005; 34: 34–9
- de Lathouder S., Gerards A. H., de Groot E. R., Valkhof M. G., Dijkmans B. A. C., Aarden L. A. Bioassay for detection of methotrexate in serum. Scand J Rheumatol 2004; 33: 167–73